Updated: Merck Q2 earnings propelled by Keytruda, Gardasil sales, but expects 'slower' growth for HPV vaccine
Merck touted billion-dollar sales growth for its cancer drug Keytruda and HPV vaccine Gardasil this quarter, and has high expectations for both as regulatory bodies have expanded indications. Yet the company couched further expectations for Gardasil, noting “slower” growth for the rest of 2023.
Keytruda sales jumped 19% to $6.3 billion because of global sales momentum in metastatic cancers and in early-stage disease such as in neoadjuvant/adjuvant triple-negative breast cancer in the US. Further, sales for Gardasil soared 47% to $2.5 billion owing to global demand specifically in China, according to its quarterly earnings report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.